Digital Biomarkers to Address COVID-19 Symptoms and Progression

The US and international effort to address the novel Coronavirus (COVID-19) pandemic is unprecedented. Experts from healthcare, public health, and policy are joining forces with experts in manufacturing and technology for the rapid deployment of innovative, lifesaving solutions. VivoSense, an expert in remote monitoring of physiological signals, is contributing to this effort through their advanced data analytics and Human Augmented AI platform.

Collecting Lifesaving COVID-19 Data at Home

Data from leading-edge wearable physiological sensors provide care providers remote monitoring solutions for patients with mild symptoms of COVID-19 and presumptive positive cases, thereby minimizing unnecessary movement of infected patients throughout the community. The VivoSense® platform integrates data from multiple wearable sensors to provide critical measures of symptoms and vital signs, including:

• • Respiratory distress
• • Heart rate
• • Heart rate variability
• • Oxygen saturation
• • Temperature

Critical indices of digital biomarkers are identified and reported through powerful algorithmic and AI procedures. The platform is architected for rapid, scalable deployment, allowing an objective assessment of large amounts of physiologic data in near real-time.

To date, there are more than 900,000 active cases of the disease, 95% of which are considered “mild” where patients are self-isolating at home. This presents a clear need for remote monitoring solutions that can aid healthcare professionals in providing rapid and appropriate care when necessary. With cases continuing to rise, epidemiologic experts must strive to gather as much information as possible on the varying ways in which the disease manifests and progresses in individuals.

The Impact Physiologic Data Has on Stopping COVID-19

We are at a critical juncture to deploy wearable sensors at scale to collect data on vital signs and symptom presentations. These data are essential for:

• • Understanding how the virus spreads through communities
• • If early detection is possible
• • How to reduce the spread from mild and asymptomatic individuals

VivoSense is committed to supporting the urgent needs of researchers, front-line healthcare professionals, and organizations in leveraging remote monitoring solutions to combat the COVID-19 pandemic.

“With more than a decade of experience in sensor-based patient monitoring, VivoSense can develop COVID-19 solutions that allow for proactive, remote interventions using accurate, actionable data. Never before has there been a clearer need for investment in sensors and analytics, which enable effective remote monitoring. VivoSense remains committed to improving healthcare interventions and driving better patient outcomes with better science.” ~ Dudley Tabakin, CEO of VivoSense.

During the COVID-19 crisis, we understand and encourage the need for everyone to stay home and avoid physical contact. Many of our academic customers are working from home and still have data to analyze. With that in mind, we have created a temporary VivoSense license so that you can continue with your research at home. Download the VivoSense trial license from https://www.vivosense.com/download-vivosense to obtain 90-day access to VivoSense at home.

To learn more about COVID-19 biomarker discovery or if you need rapid deployment, contact us to speak with one of our senior scientists.